# List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Three modes of compulsory Licensing</td>
<td>25</td>
</tr>
<tr>
<td>1.2</td>
<td>Emerging firm strategies: a categorization</td>
<td>30</td>
</tr>
<tr>
<td>1.3</td>
<td>Stages of Drug development</td>
<td>35</td>
</tr>
<tr>
<td>3.1</td>
<td>Emerging and re-emerging infectious diseases throughout the world</td>
<td>50</td>
</tr>
<tr>
<td>3.2</td>
<td>The DOTS Strategy</td>
<td>55</td>
</tr>
<tr>
<td>3.3</td>
<td>Unconcentrated sputum specimen</td>
<td>56</td>
</tr>
<tr>
<td>3.4</td>
<td>Dissemination of Tuberculosis</td>
<td>57</td>
</tr>
<tr>
<td>3.5</td>
<td>Emergence of resistant M. Tuberculosis</td>
<td>58</td>
</tr>
<tr>
<td>3.6</td>
<td>Leading corporations in US Industry of Unbranded Generics</td>
<td>86</td>
</tr>
<tr>
<td>3.7</td>
<td>Novartis History</td>
<td>87</td>
</tr>
<tr>
<td>3.8</td>
<td>Wockhardt’s manufacturing capabilities</td>
<td>92</td>
</tr>
<tr>
<td>4.1</td>
<td>DEA Literature Growth Trend</td>
<td>93</td>
</tr>
<tr>
<td>4.2</td>
<td>Path of DEA Development</td>
<td>94</td>
</tr>
<tr>
<td>4.3</td>
<td>Global Path of DEA Development</td>
<td>94</td>
</tr>
<tr>
<td>5.1</td>
<td>Technical, Allocative, and Cost efficiency</td>
<td>108</td>
</tr>
<tr>
<td>5.2</td>
<td>CCR efficiency does not exceed BCC efficiency</td>
<td>113</td>
</tr>
</tbody>
</table>

**ABBREVIATIONS**

DEA – Data Envelopment Analysis  
CCR – Charnes Cooper and Rhodes  
BCC – Banker Charnes and Cooper  
DMU – Decision making Units  
CPP – Consumer Paying Price